Lakefront Biotherapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 1 month.
- Recent price momentum is +14.0% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 2.0% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation A-
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 2.5x | Better than 99% |
| Price / Sales | 2.2x | Better than 54% |
| P/E vs own 5-yr range | 61st pctl | Better than 48% |
Growth A+
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 66.4% | Better than 97% |
| Net income CAGR (3Y) | 40.5% | Better than 85% |
| Free cash flow CAGR (3Y) | 138.0% | Better than 96% |
Profitability A
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 97.3% | Better than 99% |
| Operating margin | 45.1% | Better than 97% |
| Net margin | 28.8% | Better than 89% |
| Return on equity | 10.5% | Better than 54% |
| Return on invested capital | 9.4% | Better than 66% |
Momentum A
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 15.7% | Better than 95% |
| 6-month return | 21.2% | Better than 84% |
| 12-month return (ex latest month) | 3.2% | Better than 38% |
| Distance below 52-week high | 8.1% | Better than 88% |
Financial Health A+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 20.1x | Better than 98% |
| Debt to assets | 0.2% | Better than 97% |
| Interest coverage | 136.7x | Better than 94% |
| Free cash flow / net income | 2,110.8% | Better than 98% |
Analyst View N/A
What the Street thinks: share of Buy ratings and upside to the average target.
Not enough data to grade this factor.
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 33.39
- Open
- 33.61
- Day range
- 33.25 - 33.85
- Avg price
- 33.43
- Volume
- 162.49K
- Turnover
- 5.43M
- Turnover ratei
- 0.68%
- Volume ratioi
- 0.64
- Amplitudei
- 1.80%
- 52-week rangei
- 25.68 - 36.24
Valuation
- P/Ei
- 6.24
- P/E (TTM)i
- 2.51
- P/Bi
- 0.62
- EPSi
- 5.34
- Book value / shi
- 54.14
- Net profit
- 349.75M
- Net assets
- 3.55B
Share structure
- Market cap
- 2.18B
- Float capi
- 796.48M
- Shares out
- 65.48M
- Float sharesi
- 23.91M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
8.1% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-974.37K net over the window
Short interest
- Shares short
- 1.30M
- % of floati
- 1.97%
- Days to coveri
- 5.96
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Lakefront Biotherapeutics (LKFT)?
Lakefront Biotherapeutics last traded at 33.31. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Lakefront Biotherapeutics's market cap?
About 2.18B.
What is the P/E ratio of Lakefront Biotherapeutics?
The trailing twelve-month P/E is 2.51, below its own 5-year average of 15.34 — in the middle of its historical range (60.80% percentile). See the Valuation tab for the full history.
Does Lakefront Biotherapeutics pay a dividend?
Lakefront Biotherapeutics does not currently pay a regular dividend.
Is Lakefront Biotherapeutics a buy according to analysts?
The consensus of 2 analysts is a Buy rating, with an average 12-month price target of 45.00, which implies 35.1% upside from the current price. This is not investment advice.
What is Lakefront Biotherapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Lakefront Biotherapeutics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 16:26:21 · For reference only, not investment advice and not tailored to your situation.
Lakefront Biotherapeutics discussion 0 comments